Article Text

Download PDFPDF
043 Admission MR-PROANP levels are superior to grace score and NT-PROBNP for risk stratification in non ST-elevation acute coronary syndromes
  1. O S Dhillon1,
  2. S Q Khan1,
  3. N H Narayan1,
  4. K H Ng1,
  5. J Struck2,
  6. P A Quinn1,
  7. N G Morgenthaler2,
  8. I B Squire1,
  9. J E Dvaies1,
  10. A Bergmann2,
  11. L L Ng1
  1. 1University of Leicester, Leicester, UK
  2. 2BRAHMS, Berlin, UK


Introduction Endorsed by international guidelines, risk stratification plays a central role in the optimal management of patients with non ST-elevation (NSTE-ACS). High risk patients benefit from an early invasive approach and admission biomarker levels may help to identify this cohort. Atrial natriuretic peptide (ANP) is a recognised prognostic marker in ST elevation myocardial infarction (STEMI) and in heart failure (HF) but has not been evaluated in NSTE-ACS. The precursor of ANP is N-terminal Pro-ANP whose mid regional epitope is more stable when compared to epitopes of N- or C- terminals of pro-ANP used in previous assays.

Aims To assess the prognostic value, optimum time for sampling and a cut off value for mid regional proANP in unselected patients' with non ST elevation ACS (NSTE-ACS). We use GRACE risk score and NTproBNP as benchmark comparators.

Method and Results Plasma MRproANP was measured both on admission (taken within 36 h of symptoms) and discharge (3 to 5 days later) in 630 (437 men, median age 70.0±12.8 years) patients with NSTE-ACS. During follow up which ranged from 150 to 1059 days the primary end point of a major adverse cardiac event (MACE) was reached by 170 (27%) patients. This included 84 (13.3%) deaths, 56 (8.9%) readmissions with HF and 68 (10.8%) re-infarctions.

Admission and discharge levels were entered into 2 separate multivariate Cox regression models adjusted for important clinical and biochemical factors and Receiver Operator Characteristic (ROC) analyses performed with results shown in Abstract 43 Table 1.

Abstract 43 Table 1

PEX16 mutations identified

Admission levels demonstrated a stronger association with MACE were therefore used for comparison against GRACE score and admission NTproBNP level in a further multivariate Cox model. This showed that MRproANP (HR 5.81 p<0.001) and GRACE score calculated pre-discharge (HR 1.01 p=0.024) continued to be independently associated with the primary end point but not admission NTproBNP (HR 1.00 p=0.99) or GRACE score if calculated on presentation (HR 1.01 p=0.057). The accuracy of MRproANP at prediction of the MACE (AUC 0.76 p<0.001) was not improved by combining with GRACE score (AUC 0.72 p<0.001) both (AUC 0.76 p<0.001). ROC analyses provided the optimum cut off value for MRproANP for prediction of MACE of 165 pmol/L which gave optimum survival stratification on Kaplan–Meier analysis (log rank 90.12 p<0.001).

Conclusion MRproANP level is a potent prognostic marker of adverse events. Admission levels offer early identification of high risk NSTE-ACS patients and its role in optimising management requires further investigation.

  • atrial natriuretic peptide
  • acute coronary syndromes
  • prognosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.